Profil
Susan P.
Perrine is the founder of HemaQuest Pharmaceuticals, Inc. which was founded in 2007.
She held the title of CSO & VP-Clinical Affairs in 2010.
Dr. Perrine is also the founder of Viracta Subsidiary, Inc. Currently, she is a Professor at Boston University.
Dr. Perrine's education includes a graduate degree from Harvard University and a doctorate from Tufts University.
Aktiva positioner av Susan P. Perrine
| Företag | Position | Start |
|---|---|---|
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Tidigare kända positioner av Susan P. Perrine
| Företag | Position | Slut |
|---|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Grundare | - |
HemaQuest Pharmaceuticals, Inc.
HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics | Grundare | - |
Susan P. Perrines utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University
Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
HemaQuest Pharmaceuticals, Inc.
HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule therapeutics | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Develops proprietary viral gene activation therapy to address cancers associated with the epstein-barr virus | Health Technology |
















